BIIB
Price
$133.13
Change
+$2.77 (+2.12%)
Updated
Jun 6 closing price
Capitalization
31.34B
44 days until earnings call
LLY
Price
$769.88
Change
+$4.20 (+0.55%)
Updated
Jun 6 closing price
Capitalization
739.66B
59 days until earnings call
Interact to see
Advertisement

BIIB vs LLY

Header iconBIIB vs LLY Comparison
Open Charts BIIB vs LLYBanner chart's image
Biogen
Price$133.13
Change+$2.77 (+2.12%)
Volume$1.17M
Capitalization31.34B
Eli Lilly & Co
Price$769.88
Change+$4.20 (+0.55%)
Volume$2.07M
Capitalization739.66B
BIIB vs LLY Comparison Chart
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. LLY commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Buy and LLY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (BIIB: $127.53 vs. LLY: $719.39)
Brand notoriety: BIIB and LLY are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 91% vs. LLY: 68%
Market capitalization -- BIIB: $31.34B vs. LLY: $739.66B
BIIB [@Pharmaceuticals: Major] is valued at $31.34B. LLY’s [@Pharmaceuticals: Major] market capitalization is $739.66B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileLLY’s FA Score has 2 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • LLY’s FA Score: 2 green, 3 red.
According to our system of comparison, LLY is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 5 TA indicator(s) are bullish while LLY’s TA Score has 3 bullish TA indicator(s).

  • BIIB’s TA Score: 5 bullish, 3 bearish.
  • LLY’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than LLY.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +0.56% price change this week, while LLY (@Pharmaceuticals: Major) price change was -0.77% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.22%. For the same industry, the average monthly price growth was +3.78%, and the average quarterly price growth was +3.49%.

Reported Earning Dates

BIIB is expected to report earnings on Jul 23, 2025.

LLY is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+2.22% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LLY($740B) has a higher market cap than BIIB($31.3B). LLY has higher P/E ratio than BIIB: LLY (131.13) vs BIIB (26.95). LLY YTD gains are higher at: -6.463 vs. BIIB (-16.603). LLY has higher annual earnings (EBITDA): 8.57B vs. BIIB (2.04B). LLY has more cash in the bank: 2.93B vs. BIIB (1.05B). BIIB has less debt than LLY: BIIB (7.34B) vs LLY (25.2B). LLY has higher revenues than BIIB: LLY (34.1B) vs BIIB (9.84B).
BIIBLLYBIIB / LLY
Capitalization31.3B740B4%
EBITDA2.04B8.57B24%
Gain YTD-16.603-6.463257%
P/E Ratio26.95131.1321%
Revenue9.84B34.1B29%
Total Cash1.05B2.93B36%
Total Debt7.34B25.2B29%
FUNDAMENTALS RATINGS
BIIB vs LLY: Fundamental Ratings
BIIB
LLY
OUTLOOK RATING
1..100
955
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
10013
SMR RATING
1..100
6714
PRICE GROWTH RATING
1..100
6164
P/E GROWTH RATING
1..100
9695
SEASONALITY SCORE
1..100
7585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LLY's Valuation (81) in the Pharmaceuticals Major industry is in the same range as BIIB (87) in the Biotechnology industry. This means that LLY’s stock grew similarly to BIIB’s over the last 12 months.

LLY's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that LLY’s stock grew significantly faster than BIIB’s over the last 12 months.

LLY's SMR Rating (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (67) in the Biotechnology industry. This means that LLY’s stock grew somewhat faster than BIIB’s over the last 12 months.

BIIB's Price Growth Rating (61) in the Biotechnology industry is in the same range as LLY (64) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to LLY’s over the last 12 months.

LLY's P/E Growth Rating (95) in the Pharmaceuticals Major industry is in the same range as BIIB (96) in the Biotechnology industry. This means that LLY’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBLLY
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 12 days ago
67%
Bullish Trend 12 days ago
67%
Momentum
ODDS (%)
Bullish Trend 12 days ago
53%
Bearish Trend 12 days ago
51%
MACD
ODDS (%)
N/A
Bearish Trend 12 days ago
40%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
70%
Bearish Trend 12 days ago
55%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
56%
Bearish Trend 12 days ago
54%
Advances
ODDS (%)
Bullish Trend 20 days ago
54%
Bullish Trend 24 days ago
69%
Declines
ODDS (%)
Bearish Trend 18 days ago
70%
Bearish Trend 18 days ago
53%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
74%
N/A
Aroon
ODDS (%)
Bullish Trend 12 days ago
50%
Bullish Trend 12 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
-0.67%
AMGN - BIIB
51%
Loosely correlated
-0.38%
NVS - BIIB
47%
Loosely correlated
-1.18%
PFE - BIIB
45%
Loosely correlated
-1.82%
MRK - BIIB
41%
Loosely correlated
-1.83%
SNY - BIIB
41%
Loosely correlated
-0.76%
More

LLY and

Correlation & Price change

A.I.dvisor indicates that over the last year, LLY has been loosely correlated with AZN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then AZN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LLY
1D Price
Change %
LLY100%
-0.80%
AZN - LLY
44%
Loosely correlated
-0.82%
OGN - LLY
39%
Loosely correlated
+0.11%
BIIB - LLY
34%
Loosely correlated
-0.67%
NVS - LLY
33%
Loosely correlated
-1.18%
AMGN - LLY
33%
Poorly correlated
-0.38%
More